356 related articles for article (PubMed ID: 29219057)
1. Formulation Optimization and In-vitro and In-vivo Evaluation of Lornoxicam Ethosomal Gels with Penetration Enhancers.
Li K; Gao S; Tian B; Shi Y; Lv Q; Han J
Curr Drug Deliv; 2018; 15(3):424-435. PubMed ID: 29219057
[TBL] [Abstract][Full Text] [Related]
2. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain.
Abdelbary GA; Aburahma MH
J Liposome Res; 2015; 25(2):107-21. PubMed ID: 25058447
[TBL] [Abstract][Full Text] [Related]
3. Formulation and evaluation of proniosomes containing lornoxicam.
Madan JR; Ghuge NP; Dua K
Drug Deliv Transl Res; 2016 Oct; 6(5):511-8. PubMed ID: 27255375
[TBL] [Abstract][Full Text] [Related]
4. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.
Shah H; Nair AB; Shah J; Bharadia P; Al-Dhubiab BE
Daru; 2019 Jun; 27(1):59-70. PubMed ID: 30701460
[TBL] [Abstract][Full Text] [Related]
5. Formulation of Niosomal Gel for Enhanced Transdermal Lornoxicam Delivery: In-Vitro and In-Vivo Evaluation.
El-Ridy MS; Yehia SA; Mohsen AM; El-Awdan SA; Darwish AB
Curr Drug Deliv; 2018; 15(1):122-133. PubMed ID: 28240177
[TBL] [Abstract][Full Text] [Related]
6. Intra-articular drug delivery from an optimized topical patch containing teriflunomide and lornoxicam for rheumatoid arthritis treatment: does the topical patch really enhance a local treatment?
Xi H; Cun D; Xiang R; Guan Y; Zhang Y; Li Y; Fang L
J Control Release; 2013 Jul; 169(1-2):73-81. PubMed ID: 23567043
[TBL] [Abstract][Full Text] [Related]
7. Formulation and in vitro stability evaluation of ethosomal carbomer hydrogel for transdermal vaccine delivery.
Zhang Y; Ng W; Hu J; Mussa SS; Ge Y; Xu H
Colloids Surf B Biointerfaces; 2018 Mar; 163():184-191. PubMed ID: 29294420
[TBL] [Abstract][Full Text] [Related]
8. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema.
Gao S; Tian B; Han J; Zhang J; Shi Y; Lv Q; Li K
Int J Nanomedicine; 2019; 14():6135-6150. PubMed ID: 31447556
[No Abstract] [Full Text] [Related]
9. Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers.
Hashmat D; Shoaib MH; Ali FR; Siddiqui F
PLoS One; 2020; 15(2):e0228908. PubMed ID: 32107483
[TBL] [Abstract][Full Text] [Related]
10. Ethosomal Gel for Improving Transdermal Delivery of Thymosin β-4.
Fu X; Shi Y; Wang H; Zhao X; Sun Q; Huang Y; Qi T; Lin G
Int J Nanomedicine; 2019; 14():9275-9284. PubMed ID: 31819429
[TBL] [Abstract][Full Text] [Related]
11. In vitro & in vivo studies on lornoxicam loaded nanoemulsion gels for topical application.
Dasgupta S; Ghosh SK; Ray S; Kaurav SS; Mazumder B
Curr Drug Deliv; 2014; 11(1):132-8. PubMed ID: 24266509
[TBL] [Abstract][Full Text] [Related]
12. Design by optimization and comparative evaluation of vesicular gels of etodolac for transdermal delivery.
Madhavi N; Sudhakar B; Reddy KVNS; Ratna JV
Drug Dev Ind Pharm; 2019 Apr; 45(4):611-628. PubMed ID: 30712433
[TBL] [Abstract][Full Text] [Related]
13. Transdermal Lipid Nanocarriers: A Potential Delivery System for Lornoxicam.
Dasgupta S; Ray S; Dey S; Pal P; Mazumder B
Pharm Nanotechnol; 2017; 5(1):32-43. PubMed ID: 28948909
[TBL] [Abstract][Full Text] [Related]
14. Influence of cellulose derivative and ethylene glycol on optimization of lornoxicam transdermal formulation.
Shahzad Y; Khan Q; Hussain T; Shah SN
Int J Biol Macromol; 2013 Oct; 61():26-32. PubMed ID: 23827761
[TBL] [Abstract][Full Text] [Related]
15. Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels.
Attia MA; El-Gibaly I; Shaltout SE; Fetih GN
Int J Pharm; 2004 May; 276(1-2):11-28. PubMed ID: 15113610
[TBL] [Abstract][Full Text] [Related]
16. Combination with l-Menthol Enhances Transdermal Penetration of Indomethacin Solid Nanoparticles.
Nagai N; Ogata F; Yamaguchi M; Fukuoka Y; Otake H; Nakazawa Y; Kawasaki N
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31349657
[TBL] [Abstract][Full Text] [Related]
17. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid.
Wen MM; Farid RM; Kassem AA
J Liposome Res; 2014 Dec; 24(4):280-9. PubMed ID: 24779560
[TBL] [Abstract][Full Text] [Related]
18. Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity.
Kumbhar D; Wavikar P; Vavia P
AAPS PharmSciTech; 2013 Sep; 14(3):1072-82. PubMed ID: 23818079
[TBL] [Abstract][Full Text] [Related]
19. Proniosomes as a carrier system for transdermal delivery of tenoxicam.
Ammar HO; Ghorab M; El-Nahhas SA; Higazy IM
Int J Pharm; 2011 Feb; 405(1-2):142-52. PubMed ID: 21129461
[TBL] [Abstract][Full Text] [Related]
20. Design of meloxicam and lornoxicam transdermal patches: Preparation, physical characterization, ex vivo and in vivo studies.
Yener G; Üner M; Gönüllü Ü; Yildirim S; Kiliç P; Aslan SS; Barla A
Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1466-73. PubMed ID: 21048338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
